We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
Read MoreHide Full Article
Key Takeaways
Eton's second quarter of 2026 product sales rose 99%, fueled by strong portfolio growth and Hemangeol.
Eton raised 2026 revenue guidance above $145 million, with an adjusted EBITDA margin of at least 35%.
Hemangeol led Q2 growth, while new launches and pipeline assets expand future revenue opportunities.
Shares of Eton Pharmaceuticals (ETON - Free Report) have gained about 108% over the past six months compared with the industry’s 0.7% growth, fueled by growing investor confidence in the company’s strong commercial execution, rapid revenue growth and an expanding rare-disease portfolio. The company’s improving financial performance and several new product opportunities have strengthened investor confidence in its growth outlook.
Image Source: Zacks Investment Research
Strong Product Sales Drive ETON’s Growth
The biggest catalyst has been Eton’s accelerating product sales. In the first half of 2026, product sales reached $61.9 million compared with $32.9 million in the year-ago period. In the second quarter, revenues jumped 99% year over year to $37.6 million, supported by strong portfolio growth and the addition of Hemangeol.
Eton generates revenues from a portfolio of rare-disease and specialty products, including Increlex, Alkindi Sprinkle, Galzin, Carglumic Acid, Khindivi, Hemangeol and Desmoda. Growth in several of these products, particularly Increlex, Alkindi Sprinkle, Galzin and Carglumic Acid, helped drive the company’s first-half performance.
Higher 2026 Guidance Supports Investor Confidence
Eton has repeatedly raised its 2026 outlook. The company has raised its 2026 financial outlook twice this year, reflecting strong business momentum. In March, the company initially expected revenues to exceed $110 million. Following strong first-quarter results, it raised the forecast to more than $120 million in May. After another strong second quarter, Eton raised its revenue outlook again in August to more than $145 million. Eton expects an adjusted EBITDA margin of at least 35%, highlighting improving operating leverage. This upward revision has strengthened expectations for continued earnings growth.
Eton’s Hemangeol Adds a Major Growth Driver
The successful relaunch of Hemangeol has strengthened Eton’s commercial portfolio and emerged as an important growth driver. Eton relaunched the product in May 2026 after acquiring the rights to the treatment.
Hemangeol is the only FDA-approved treatment for infantile hemangiomas requiring systemic therapy. Treatment is generally initiated between five weeks and five months of age, making timely access important for eligible infants. Eton supports patients through its Eton Cares program and a dedicated rare-disease specialty pharmacy model.
The company successfully transitioned approximately 95% of existing Hemangeol patients to its Eton Cares program by the end of June, ahead of expectations. The product is expected to contribute meaningfully to Eton’s revenue growth in 2026 and beyond.
Eton’s Pipeline & Portfolio Expansion Creates New Opportunities
Eton is expanding its rare-disease portfolio through new product launches, pipeline acquisitions and label expansions. These initiatives could provide additional revenue opportunities and reduce the company’s dependence on its existing commercial products.
Eton is broadening its commercial portfolio with several new opportunities. Desmoda, an oral desmopressin solution, was launched earlier this year for the management of central diabetes insipidus in patients of all ages, which could contribute to future revenue growth. In late July, the company announced plans to pursue a label expansion for its marketed drug, Khindivi to include children under five years of age with adrenocortical insufficiency. A potential FDA approval is expected in the first half of 2027.
In September, it launched Impavido (miltefosine) in the United States for patients with leishmaniasis after acquiring exclusive commercialization rights. Eton is integrating Impavido into its rare-disease commercial infrastructure and patient-support program, creating another potential source of revenues.
Eton strengthened its pipeline in August by acquiring ASN-001, a late-stage product candidate for the treatment of moderate infantile hemangiomas. The company plans to conduct a bioavailability study before submitting a new drug application in the second half of 2027. Management believes ASN-001 could become its largest pipeline revenue opportunity, offering significant long-term growth potential.
Eton is also advancing Amglidia, a pediatric endocrinology pipeline candidate, which has received FDA Fast Track designation and ET-700, an extended-release zinc acetate candidate being developed for Wilson disease. Together, with ASN-001 and the Khindivi label expansion, these programs strengthen Eton’s pipeline and provide multiple opportunities for future growth.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. AMRN’s shares have lost 13.5% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Alnylam Pharmaceuticals have decreased from $8.65 to $8.63 for 2026. Over the same period, estimates for 2027 earnings per share have narrowed from $12.13 to $12.04. ALNY’s shares have plunged 43.7% year to date.
Alnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 27.58%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeuticshave narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX’s shares have plunged 82.3% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.
View the Zacks #1 Rank List
Image: Bigstock
ETON Stock Surges 108% in Six Months: Here's What You Need to Know
Key Takeaways
Shares of Eton Pharmaceuticals (ETON - Free Report) have gained about 108% over the past six months compared with the industry’s 0.7% growth, fueled by growing investor confidence in the company’s strong commercial execution, rapid revenue growth and an expanding rare-disease portfolio. The company’s improving financial performance and several new product opportunities have strengthened investor confidence in its growth outlook.
Image Source: Zacks Investment Research
Strong Product Sales Drive ETON’s Growth
The biggest catalyst has been Eton’s accelerating product sales. In the first half of 2026, product sales reached $61.9 million compared with $32.9 million in the year-ago period. In the second quarter, revenues jumped 99% year over year to $37.6 million, supported by strong portfolio growth and the addition of Hemangeol.
Eton generates revenues from a portfolio of rare-disease and specialty products, including Increlex, Alkindi Sprinkle, Galzin, Carglumic Acid, Khindivi, Hemangeol and Desmoda. Growth in several of these products, particularly Increlex, Alkindi Sprinkle, Galzin and Carglumic Acid, helped drive the company’s first-half performance.
Higher 2026 Guidance Supports Investor Confidence
Eton has repeatedly raised its 2026 outlook. The company has raised its 2026 financial outlook twice this year, reflecting strong business momentum. In March, the company initially expected revenues to exceed $110 million. Following strong first-quarter results, it raised the forecast to more than $120 million in May. After another strong second quarter, Eton raised its revenue outlook again in August to more than $145 million. Eton expects an adjusted EBITDA margin of at least 35%, highlighting improving operating leverage. This upward revision has strengthened expectations for continued earnings growth.
Eton’s Hemangeol Adds a Major Growth Driver
The successful relaunch of Hemangeol has strengthened Eton’s commercial portfolio and emerged as an important growth driver. Eton relaunched the product in May 2026 after acquiring the rights to the treatment.
Hemangeol is the only FDA-approved treatment for infantile hemangiomas requiring systemic therapy. Treatment is generally initiated between five weeks and five months of age, making timely access important for eligible infants. Eton supports patients through its Eton Cares program and a dedicated rare-disease specialty pharmacy model.
The company successfully transitioned approximately 95% of existing Hemangeol patients to its Eton Cares program by the end of June, ahead of expectations. The product is expected to contribute meaningfully to Eton’s revenue growth in 2026 and beyond.
Eton’s Pipeline & Portfolio Expansion Creates New Opportunities
Eton is expanding its rare-disease portfolio through new product launches, pipeline acquisitions and label expansions. These initiatives could provide additional revenue opportunities and reduce the company’s dependence on its existing commercial products.
Eton is broadening its commercial portfolio with several new opportunities. Desmoda, an oral desmopressin solution, was launched earlier this year for the management of central diabetes insipidus in patients of all ages, which could contribute to future revenue growth. In late July, the company announced plans to pursue a label expansion for its marketed drug, Khindivi to include children under five years of age with adrenocortical insufficiency. A potential FDA approval is expected in the first half of 2027.
In September, it launched Impavido (miltefosine) in the United States for patients with leishmaniasis after acquiring exclusive commercialization rights. Eton is integrating Impavido into its rare-disease commercial infrastructure and patient-support program, creating another potential source of revenues.
Eton strengthened its pipeline in August by acquiring ASN-001, a late-stage product candidate for the treatment of moderate infantile hemangiomas. The company plans to conduct a bioavailability study before submitting a new drug application in the second half of 2027. Management believes ASN-001 could become its largest pipeline revenue opportunity, offering significant long-term growth potential.
Eton is also advancing Amglidia, a pediatric endocrinology pipeline candidate, which has received FDA Fast Track designation and ET-700, an extended-release zinc acetate candidate being developed for Wilson disease. Together, with ASN-001 and the Khindivi label expansion, these programs strengthen Eton’s pipeline and provide multiple opportunities for future growth.
Eton Pharmaceuticals, Inc. Price and Consensus
Eton Pharmaceuticals, Inc. price-consensus-chart | Eton Pharmaceuticals, Inc. Quote
ETON's Zacks Rank & Stocks to Consider
Eton currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Amarin (AMRN - Free Report) and Alnylam Pharmaceuticals (ALNY - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy) each and Aldeyra Therapeutics (ALDX - Free Report) , carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, loss per share estimates for Amarin have narrowed from 65 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 51 cents to 50 cents. AMRN’s shares have lost 13.5% year to date.
Amarin’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 62.27%.
Over the past 60 days, earnings per share estimates for Alnylam Pharmaceuticals have decreased from $8.65 to $8.63 for 2026. Over the same period, estimates for 2027 earnings per share have narrowed from $12.13 to $12.04. ALNY’s shares have plunged 43.7% year to date.
Alnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, the average surprise being 27.58%.
Over the past 60 days, loss per share estimates for Aldeyra Therapeuticshave narrowed from 43 cents to 39 cents for 2026. Over the same period, estimates for 2027 loss per share have narrowed from 22 cents to 16 cents. ALDX’s shares have plunged 82.3% year to date.
Aldeyra Therapeutics’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 29.25%.